Health
Lilly’s Weight-Loss Drug Improved Sleep Apnea in Studies
- Zepbound reduced breathing issues during sleep by up to 63%
- Drugmaker plans to submit results to US regulators mid-year
This article is for subscribers only.
Eli Lilly & Co.’s weight-loss drug Zepbound improved sleep-related breathing problems in highly anticipated studies that may convince more insurers to cover the $1,000-a-month treatment.
In two late-stage trials of patients with obstructive sleep apnea, a condition closely linked to obesity, Zepbound reduced the number of times breathing slowed or stopped during sleep by up to 63% from the baseline, Lilly said in a statement Wednesday. The result topped Jefferies analysts’ expectations that the trials would likely show a reduction of up to 55%.